Agilent Technologies Collaborates with Gachon University
News Jul 23, 2012
Agilent Technologies Inc. and Gachon University of Medicine and Science today announced a collaboration in the field of biomarker discovery using proteomics and glycoproteomics. The College of Pharmacy at Gachon University is world-renowned for its research in preventing and treating cancer and diabetes.
Proteomics refers to the large-scale experimental analysis of proteins and is used to identify potential new drugs for the treatment of disease. Glycoproteomics is the study of a cell, tissue or organism's glycan and glycoprotein content at any given time. Glycoproteomics encompasses two completely different classes of molecules with very different chemistries, compositions and structures.
"As scientists, we're always looking for more information that we can glean from every sample," said professor HooKeun Lee, head of Gachon University of Medicine and Science. "In this case, we need high-resolution separation and analysis of glycans and glycopeptides. With the right technologies helping us, Gachon is contributing to the global medical community by providing them the breakthrough in the path towards personalized drugs for each individual. Agilent will provide Gachon University with most sophisticated bio-analytical instruments and early access to novel technologies to meet our current and future needs."
Under a memorandum of understanding, the laboratory at the College of Pharmacy in Gachon University of Medicine and Science will serve as Agilent's beta test site for complete glycoproteomics and biomarker discovery workflow solutions.
"Glycoproteomics is a key focal point in various aspects of life sciences research," said Rod Minett, general manager of Agilent's life sciences business in South Korea and the South Asia Pacific region. "Through this collaboration, we hope to help scientists and researchers advance their research, unlock the genetic causes of disease and accelerate the discovery and development of new drugs."
An immunotherapeutic antibody therapy re-educates macrophages to activate passivated cytotoxic T cells to kill cancer. The antibody therapy prevented the growth of tumors in several mouse models. The development of the therapy has now progressed to patient testing in a phase I/II clinical trial.READ MORE